Linden Thomas Advisory Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Linden Thomas Advisory Services’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.53M	Buy	176,004 +12,413	+8%	+$366K	0.45%	42
2026 Q1	$4.05M	Buy	163,591 +23,693	+17%	+$564K	0.39%	63
2025 Q4	$3.27M	Buy	139,898 +4,317	+3%	+$96.2K	0.33%	78
2025 Q3	$2.67M	Buy	135,581 +8,155	+6%	+$168K	0.27%	108
2025 Q2	$2.77M	Buy	127,426 +92,193	+262%	+$2.18M	0.3%	90
2025 Q1	$854K	Buy	35,233 +2,594	+8%	+$58.4K	0.11%	302
2024 Q4	$681K	Buy	32,639 +5,732	+21%	+$123K	0.09%	347
2024 Q3	$535K	Buy	26,907 +5,581	+26%	+$103K	0.07%	370
2024 Q2	$330K	Buy	21,326 +4,583	+27%	+$71.3K	0.05%	395
2024 Q1	$267K	Buy	16,743 +5,666	+51%	+$85.4K	0.04%	396
2023 Q4	$186K	Buy	+11,077	New	+$151K	0.03%	412

Other funds holding CPRX

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

OLA

Oliver Luxxe Assets Gladstone, New Jersey $680M AUM 47.51% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Linden Thomas Advisory Services's CPRX Position: Q2 2026 in Review

Linden Thomas Advisory Services increased its Catalyst Pharmaceutical (CPRX) stake by 7.6% in Q2 2026, buying an estimated $366K and bringing the position to 176,004 shares worth $5.53M. The position accounts for 0.45% of the portfolio, ranked #42.

Linden Thomas Advisory Services first reported a position in CPRX in Q4 2023 and has held it in 11 quarters since. 36 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Linden Thomas Advisory Services held 176,004 shares of Catalyst Pharmaceutical worth $5.53M as of Q2 2026.
Linden Thomas Advisory Services bought 12,413 Catalyst Pharmaceutical shares in Q2 2026, an estimated $366K.
Catalyst Pharmaceutical made up 0.45% of Linden Thomas Advisory Services's portfolio in Q2 2026, its #42 holding.
Linden Thomas Advisory Services first reported a position in Catalyst Pharmaceutical in Q4 2023 and has held it in 11 quarters since.
36 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q2 2026, filed 16 Jul 2026.